Technology
Ninalia NIPT by Eurofins Biomnis is performed with an overall, pangenomic method based on high-throughput DNA sequencing (Massively-Parallel Sequencing, or MPS). Eurofins Biomnis has collaborated with Illumina, an American biotechnology company, specialising in sequencing the human genome. Ninalia NIPT offers the best performance in terms of sensitivity, specificity, and detection rates, etc. for non-invasive prenatal screening.
Over 250,000 Ninalia tests have been performed to date at Eurofins Biomnis.
Our geneticists
The qualified prenatal diagnosis geneticists responsible for testing at Eurofins Biomnis provide optimum support to prescribers and laboratories in the implementation of this test, from determining whether the test is appropriate through to reporting results.
Our activities
Eurofins Biomnis is a leading provider of specialised medical pathology services in Europe, established by Marcel Mérieux in 1897. It is devoted primarily to specialised analyses requiring expert technologies and demanding high levels of expertise. Eurofins Biomnis is involved in all areas of clinical biology, with a focus on foetal and prenatal diagnostics.
